Recce Pharmaceuticals

Capital Raise April 2025

Corporate Governance

Why Invest

News and Media

Announcements

Home

Titillium Web

Recce's Entitlement Offer is now live! Visit the page for instructions on how to participate

Recce Pharmaceuticals Limited is developing a New Class of Synthetic Anti-Infectives with the potential to overcome antibiotic-resistant superbugs – the challenge of all antibiotics to date.

 of Phase II/III clinical trials across multiple key geographies with significant revenue catalysts over the next 12 months. This capital raising presents a unique opportunity to support Recce through a transformative phase, with 

Capital raising will fund the company through to completion of registrational Phase III Indonesian trials: 

Phase III DFI Registrational Topical Clinical Trial in Indonesia – the catalyst for revenue in 2026;

Commencement of Phase III Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) Registrational Topical Clinical Trial in Australia; and

Additional clinical activities, Investigational New Drug Application to the FDA and working capital.

Provides necessary capital to see Indonesian clinical trials for topical treatments through to commercialisation

Participation in the Entitlement Offer will be open to Recce shareholders who are registered holders of Shares at 7:00pm (AEST) on Wednesday, 16 April 2025 (Record Date) and who have a registered address in Australia, New Zealand, Hong Kong, Singapore and who are Accredited Investors in the United States (Eligible Shareholders).

Click on the button below to sign in to your Automic investor account.

If you have any questions, please contact please contact the Share Registry on 1300 288 664 (callers within Australia) or +61 2 9698 5414 (callers outside Australia) between 8:30am and 7:00pm (AEST), Monday to Friday (excluding public holidays) on a Business Day during the Entitlement Offer period.

The Company has received a binding commitment from an Australian-based private investor to subscribe for approximately 17.9 million New Shares in the Company at the Offer Price to raise approximately $5.0 million (before costs).  In addition, the Company is undertaking a pro-rata nonrenounceable Entitlement Offer of one (1) New Share for every six (6) existing fully paid ordinary Shares held by eligible shareholders at the Offer Price to raise up to a further A$10.8 million (before costs). 



The Offer Price of A$0.28 per New Share under the Capital Raising represents a:

 
• 13.8% discount to the last closing price of A$0.325 on 9 April 2025; 
• 19.8% discount to the 5-day Volume Weighted Average Price (VWAP) of A$0.3492 up to, and including, 9 April 2025; and 
• 11.4% discount to the theoretical ex-rights price (TERP) of A$0.3162 as at 9 April 2025 including shares issued under the Placement and full take-up under the Entitlement Offer.